Adverse Reactions and Risk Factors of Tislelizumab:A Retrospective Study
Objective To provide data for medication safety by analyzing the risk factors of immune-related adverse events(irAEs)in cancer patients treated with tislelizumab.Methods Patients who received tislelizumab for anti-tumor therapy from December 2021 to January 2023 were selected,who were divided into the irAEs group and non-irAEs group according to the occurrence of irAEs after administration of tislelizumab.The basic data on the two groups was compared,and the risk factors of irAEs were screened via multivariate logistic regression analysis.Results A total of 121 patients were enrolled in this study,including 80 patients who developed irAEs and 41 patients who did not.In the irAEs group,the ratio of males to females was 1.58∶1 and the average age was(60.48±10.57)years old.Fifty of these cases(41.7%)were diagnosed with biliary tract tumor while 31(38.8%)received chemotherapy combined with targeted therapy.Sixty-seven cases(35.8%)involved the blood system and 38 cases(20.3%)involved the digestive system.More than half of the patients improved after treatment.Logistic regression analysis suggested that long-course cancer(OR=1.040,P=0.005),combined medication(P<0.005)and billiary tract tumors(OR=8.297,P=0.001)were the risk factors for irAEs in cancer patients.Conclusion During the treatment of cancer patients with tislelizumab,clinicians should be alert to irAEs in patients,especially those who were female,senile,with long-course cancer,recipients of combined medication or with biliary tract tumors.
NETL
NSTL
万方数据
